GT BIOPHARMA, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
GT BIOPHARMA, INC. (GTBP) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $18.37 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2022-08-15
- GT BIOPHARMA, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-06-30 was -$8.37M.
- GT BIOPHARMA, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-03-31 was $26.74M.
- GT BIOPHARMA, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2020 was $5.30M.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|
| 2022-06-30 | -$8.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $18.37M 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $26.74M 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $23.01M 10-Q · filed 2022-08-15 | $31.98M 10-K · filed 2022-03-28 | ||
| 2020-12-31 | $5.30M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |